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Background
An exaggerated pain sensitivity is the dominant feature of
inflammatory and neuropathic pain both in the clinical
setting and in experimental animal models. It manifests as
pain in response to normally innocuous stimuli (allody-
nia), increased response to noxious stimuli (hyperalgesia)
or spontaneous pain, and can persist long after the initial
injury is resolved. Research over the last decades has
revealed that several signaling pathways in the spinal cord
essentially contribute to the pain sensitization. To test the
contribution of cGMP produced by NO-sensitive guanylyl
cyclase (NO-GC) to pain sensitization, we investigated the
localization of NO-GC in the spinal cord and in dorsal
root ganglia, and we characterized the nociceptive behav-
ior of mice deficient in NO-GC (GC-KO mice).
Results
We show that NO-GC (β1 subunit) is distinctly expressed
in neurons of the mouse spinal cord, while its distribution
in dorsal root ganglia is restricted to non-neuronal cells.
GC-KO mice exhibited a considerably reduced nocicep-
tive behavior in models of inflammatory or neuropathic
pain, but their responses to acute pain were not impaired.
Moreover, GC-KO mice failed to develop pain sensitiza-
tion induced by spinal administration of drugs releasing
NO. Surprisingly, during spinal nociceptive processing
cGMP produced by NO-GC may activate signaling path-
ways different from cGMP-dependent protein kinase I
(cGKI), while cGKI can be activated by natriuretic peptide
receptor-B (NPR-B) dependent cGMP production.
Conclusion
Taken together, our results provide evidence that NO-GC
has a dominant role in the development of exaggerated
pain sensitivity during inflammatory and neuropathic
pain. Furthermore, beside the NO-mediated cGMP syn-
thesis, cGMP produced by NPR-B contributes to pain sen-
sitization by activation of cGKI.
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